EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

Xiang Gao, Haolin Zhao, Jiao Liu, Min Wang, Zhihong Dai, Wenjun Hao, Yanlong Wang, Xiang Wang, Min Zhang, Pixu Liu, Hailing Cheng iD, Zhiyu Liu

Advanced Science · 2024-08 · 11 (30)

DOI: 10.1002/advs.202401396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 10.06.2024. Verfasst von Xiang Gao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Second Hospital of Dalian Medical University, Dalian, 116023, China. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Prostatic Neoplasms, Castration-Resistant, Benzamides, Copper. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China, Natural Science Foundation of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the initial efficacy of enzalutamide in castration‐resistant prostate cancer (CRPC), inevitable resistance remains a significant challenge. Here, the synergistic induction of copper‐dependent cell death (cuproptosis) in CRPC cells is reported by enzalutamide and copper ionophores (elesclomol/disulfiram). Mechanistically, enzalutamide treatment increases mitochondrial dependence in CRPC cells, rendering them susceptible to cuproptosis, as evidenced by specific reversal with the copper chelator tetrathiomolybdate. This susceptibility is characterized by hallmarks of cuproptosis, including lipoylated protein aggregation and iron‐sulfur cluster protein instability. Interestingly, the mitochondrial matrix reductase, FDX1, specifically correlates with elesclomol sensitivity, suggesting a potential mechanistic divergence between the two copper ionophores. Notably, this synergistic effect extends beyond in vitro models, demonstrating efficacy in 22Rv1 xenografts, mouse Pten p53 knockout organoids. Importantly, enzalutamide significantly enhances copper ionophore‐mediated cytotoxicity in enzalutamide‐resistant cells. Collectively, these findings indicate that enzalutamide and copper ionophores synergistically induce cuproptosis, offering a promising therapeutic avenue for CRPC, potentially including enzalutamide‐resistant cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylthiohydantoinProstatic Neoplasms, Castration-ResistantBenzamidesCopperNitrilesCell DeathMaleMiceAnimalsHumansCell Line, TumorDrug Resistance, NeoplasmDisease Models, AnimalDisulfiram

Stichwörter der Autor:innen

CRPCcopper ionophorecuproptosisenzalutamide

Substanzen

enzalutamidePhenylthiohydantoinBenzamidesCopperNitrilesDisulfiram

Autor:innen und Institutionen

  • Department of Urology, Second Hospital of Dalian Medical University, Dalian, 116023, China.
  • Dalian Key Laboratory of Molecular Targeted Cancer Therapy, Cancer Institute, The Second Hospital of Dalian Medical University, Dalian, 116023, China.
  • Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
  • Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116023, China.

ORCID-Profile: Hailing Cheng

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation of China
  • Natural Science Foundation of Liaoning Province
  • Foundation of Liaoning Province Education Administration
  • Wenzhou Medical University
  • Liaoning Revitalization Talents Program
  • The United Foundation for Dalian Institute of Chemical Physics Chinese Academy of Sciences and the Second Hospital of Dalian Medical University

Zitieren

APA

Gao, X., Zhao, H., Liu, J., Wang, M., Dai, Z., Hao, W., Wang, Y., Wang, X., Zhang, M., Liu, P., Cheng, H., & Liu, Z. (2024). Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death. Advanced Science, 11(30). https://doi.org/10.1002/advs.202401396

Vancouver

Gao X, Zhao H, Liu J, Wang M, Dai Z, Hao W, et al. Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death. Advanced Science. 2024;11(30). doi:10.1002/advs.202401396

BibTeX
@article{Gao2024,
  author = {Gao, Xiang and Zhao, Haolin and Liu, Jiao and Wang, Min and Dai, Zhihong and Hao, Wenjun and Wang, Yanlong and Wang, Xiang and Zhang, Min and Liu, Pixu and Cheng, Hailing and Liu, Zhiyu},
  title = {Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {30},
  doi = {10.1002/advs.202401396}
}
Kostenlos starten →